^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAR.B7-H3 T

    i
    Other names: CAR.B7-H3 T, CAR.B7-H3T, Chimeric antigen receptor T cells with B7.H3 molecular target, Autologous CAR-T Cells Targeting B7-H3
    Associations

    News

    Trials
    Company:
    UNC Lineberger Comprehensive Cancer Center
    Drug class:
    B7-H3-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    24d
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: May 2028 --> May 2030 | Trial primary completion date: May 2026 --> May 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    3ms
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Apr 2036 | Trial primary completion date: Mar 2026 --> Apr 2036
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    4ms
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 --> Apr 2030 | Trial primary completion date: Jun 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CAR.B7-H3 T
    1year
    Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    over1year
    Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=21 --> 7 | Trial primary completion date: Feb 2025 --> Feb 2024
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    CD276 (CD276 Molecule) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    almost2years
    Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc (clinicaltrials.gov)
    P1, N=36, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Oct 2024 --> May 2030
    Trial primary completion date • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T
    almost2years
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T
    almost2years
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    almost2years
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    2years
    Autologous CAR-T Cells Targeting B7-H3 in PDAC (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Jun 2024 --> Sep 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CAR.B7-H3 T
    over2years
    Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Mar 2024 --> Jul 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T
    over2years
    Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • CAR.B7-H3 T